Search

• 

  Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

  Behind the science magazine

  GSK scientists spent decades researching respiratory syncytial virus to understand better how to prevent the disease

  https://www.gsk.com/en-gb/behind-the-science-magazine/rsv-symptoms-risks-protection/

  First published: 10 March 2025

• GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024

  Media

  60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease-portfolio-at-idweek-2024/

  First published: 10 October 2024

• GSK gathers global experts to discuss role of vaccines in protecting people and the planet

  Media

  'Palio’ meeting to address growing threat to human health from infectious disease and its links to nature loss and climate change.

  https://www.gsk.com/en-gb/media/press-releases/gsk-gathers-global-experts-to-discuss-role-of-vaccines-in-protecting-people-and-the-planet/

  First published: 07 July 2022

• 

  Fresh insights could finally help us tackle RSV

  Behind the science magazine

  The 60 year search for solutions for RSV

  https://www.gsk.com/en-gb/behind-the-science-magazine/fresh-insights-could-finally-help-us-tackle-rsv/

  First published: 11 February 2022

• Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19

  Media

  The DSMB has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature.

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-provide-update-on-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/

  First published: 03 March 2021

• 

  Back to school immunity: vaccination catch-ups are needed to stop the escalation of preventable diseases in children

  Behind the science magazine

  Medical experts say now is the time to catch up on essential immunisation programs to ensure young people and communities are protected

  https://www.gsk.com/en-gb/behind-the-science-magazine/child-immunity-gap-vaccination-catch-up/

  First published: 12 September 2023

• 

  Health security

  Responsibility

  At GSK, we’re uniting science, technology and talent to get ahead of health security threats

  https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/health-security/

  First published: 18 March 2024

• GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

  Media

  GSK announces a major conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses

  https://www.gsk.com/en-gb/media/press-releases/gsk-plc-announces-major-three-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders/

  First published: 22 April 2014

• Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment

  Media

  Phase 2/3 study will investigate the safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/

  First published: 31 August 2020

• Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19

  Media

  Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19/

  First published: 10 March 2021